We are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging our extensive expertise in E3 ligases together with our proprietary DNA-encoded libraries, we have built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell.
Market Cap | 566.828 Million | Shares Outstanding | 44.738 Million | Avg 30-day Volume | 920.424 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.09 |
Price to Revenue | 21.1538 | Debt to Equity | 0.0 | EBITDA | -136.108 Million |
Price to Book Value | 2.376 | Operating Margin | -396.1234 | Enterprise Value | 341.182 Million |
Current Ratio | 4.247 | EPS Growth | -28.727 | Quick Ratio | 4.057 |
1 Yr BETA | 1.3726 | 52-week High/Low | 37.43 / 7.52 | Profit Margin | -394.2142 |
Operating Cash Flow Growth | -309.2488 | Altman Z-Score | 2.1065 | Free Cash Flow to Firm | -125.661 Million |
Earnings Report | 2022-07-07 |
Please sign in first
none
2.8 Thousand total shares from 4 transactions
77.3 Thousand total shares from 5 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
VAN HOUTE HANS CHIEF FINANCIAL OFFICER |
|
70,522 | 2022-05-31 | 3 |
|
17,500 | 2022-05-05 | 1 | |
|
17,500 | 2022-05-05 | 1 | |
|
17,500 | 2022-05-05 | 3 | |
|
17,500 | 2022-05-05 | 3 | |
|
17,500 | 2022-05-05 | 1 | |
|
17,500 | 2022-05-05 | 1 | |
WOLFF STEFANI EVP AND COO |
|
16,024 | 2022-04-30 | 3 |
HANSEN GWENN CHIEF SCIENTIFIC OFFICER |
|
83,502 | 2022-04-30 | 11 |
RING CHRISTINE GENERAL COUNSEL |
|
36,327 | 2022-04-30 | 11 |
SANDS ARTHUR T PRESIDENT, CEO |
|
300,000 | 2022-01-20 | 1 |
BEAURANG PIERRE CHIEF BUSINESS OFFICER |
|
127,558 | 2021-08-10 | 2 |
|
No longer subject to file | 2021-05-07 | 0 | |
|
No longer subject to file | 2021-05-07 | 0 | |
|
3,682,941 | 2021-05-06 | 0 | |
|
17,500 | 2021-05-06 | 0 | |
|
17,500 | 2021-05-06 | 0 | |
|
No longer subject to file | 2020-07-28 | 0 | |
WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P. |
|
No longer subject to file | 2020-07-28 | 0 |
|
124,999 | 2020-07-28 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-06-01 16:57:59 -0400 | 2022-05-31 | M | 68,333 | d | 0 | direct | ||||||||||
2022-06-01 16:57:59 -0400 | 2022-05-31 | M | 68,333 | $0.84 | a | 70,522 | direct | 16.2816 | 20.462 | 29.923 | 5 | 0.0 | 1 | |||
2022-05-06 17:43:06 -0400 | 2022-05-05 | A | 17,500 | a | 17,500 | direct | ||||||||||
2022-05-06 17:44:38 -0400 | 2022-05-05 | A | 17,500 | a | 17,500 | direct | ||||||||||
2022-05-06 17:40:18 -0400 | 2022-05-05 | A | 17,500 | a | 17,500 | direct | ||||||||||
2022-05-06 17:41:33 -0400 | 2022-05-05 | A | 17,500 | a | 17,500 | direct | ||||||||||
2022-05-06 17:23:28 -0400 | 2022-05-05 | A | 17,500 | a | 17,500 | direct | ||||||||||
2022-05-06 17:22:28 -0400 | 2022-05-05 | A | 17,500 | a | 17,500 | direct | ||||||||||
2022-05-03 19:05:41 -0400 | 2022-05-02 | S | 1,098 | $11.75 | d | 17,151 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | ||
2022-05-03 19:03:47 -0400 | 2022-05-02 | S | 697 | $11.75 | d | 2,189 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | ||
2022-05-03 19:04:41 -0400 | 2022-05-02 | S | 330 | $11.75 | d | 632 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | ||
2022-05-03 19:03:03 -0400 | 2022-05-02 | S | 660 | $11.75 | d | 3,403 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | ||
2022-05-03 19:05:41 -0400 | 2022-04-30 | M | 3,206 | a | 18,249 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | |||
2022-05-03 19:03:03 -0400 | 2022-04-30 | M | 1,924 | a | 4,063 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | |||
2022-05-03 19:05:41 -0400 | 2022-04-30 | M | 3,206 | d | 48,102 | direct | ||||||||||
2022-05-03 19:03:47 -0400 | 2022-04-30 | M | 2,886 | d | 43,291 | direct | ||||||||||
2022-05-03 19:03:47 -0400 | 2022-04-30 | M | 2,886 | a | 2,886 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | |||
2022-05-03 19:04:41 -0400 | 2022-04-30 | M | 962 | d | 14,430 | direct | ||||||||||
2022-05-03 19:04:41 -0400 | 2022-04-30 | M | 962 | a | 962 | direct | -10.431 | -24.1379 | -16.1207 | 1.8103 | 25 | -32.069 | 17 | |||
2022-05-03 19:03:03 -0400 | 2022-04-30 | M | 1,924 | d | 28,861 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
NURIX THERAPEUTICS INC NRIX | 2022-06-24 22:15:03 UTC | 0.9436 | 0.6264 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 21:45:03 UTC | 0.9436 | 0.6264 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 21:15:04 UTC | 0.9436 | 0.6264 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 20:45:03 UTC | 0.949 | 0.621 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 20:15:03 UTC | 0.949 | 0.621 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 19:45:03 UTC | 0.949 | 0.621 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 19:15:03 UTC | 0.949 | 0.621 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 18:45:03 UTC | 1.026 | 0.544 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 18:15:04 UTC | 1.026 | 0.544 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 17:45:03 UTC | 1.026 | 0.544 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 17:15:03 UTC | 1.026 | 0.544 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 16:45:03 UTC | 0.9716 | 0.5984 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 16:15:03 UTC | 0.9716 | 0.5984 | 600000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 15:45:03 UTC | 0.9716 | 0.5984 | 450000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 15:15:03 UTC | 0.9716 | 0.5984 | 450000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 14:45:03 UTC | 0.8437 | 0.7263 | 450000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 14:15:03 UTC | 0.8437 | 0.7263 | 450000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 13:45:03 UTC | 0.8437 | 0.7263 | 450000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 13:15:03 UTC | 0.8437 | 0.7263 | 450000 |
NURIX THERAPEUTICS INC NRIX | 2022-06-24 12:45:03 UTC | 0.8437 | 0.7263 | 450000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|